Drug Discovery & Development
News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.
Kura Oncology Advances Phase I/II Trial for Menin Inhibitor in Advanced AML
The company is currently enrolling around a dozen AML patients with NPM1 mutations or KMT2A rearrangements into two Phase Ib cohorts.
Pfizer Studying Talzenna in Advanced Prostate Cancer Patients With DNA Damage Response Gene Defects
The Phase III trial will randomize metastatic castration-sensitive prostate cancer patients to Talzenna plus Xtandi or just Xtandi.
Clovis Oncology Begins Study of FAP-2286 Targeted Imaging Agent, Radionuclide Therapy
The Phase I/II LuMIERE study is enrolling patients with different types of tumors at the O'Neal Comprehensive Cancer Center in Alabama.
AnHeart Therapeutics Begins Phase II Basket Trial of Taletrectinib in NTRK-Positive Solid Tumors
AnHeart licensed taletrectinib this month to Innovent Biologics, which will codevelop and commercialize the drug in greater China.
Caris Life Sciences, Elevation Oncology Team on Targeted Drug Development
The companies are working together to mine Caris' multiomic data for new cancer drug targets, sharing drug/diagnostic development costs for chosen candidates.